Literature DB >> 7359080

Measurement of tamoxifen in serum by thin-layer densitometry.

H K Adam, M A Gay, R H Moore.   

Abstract

A method is described for the determination of tamoxifen in serum. The drug was extracted from the serum and separated from its metabolites by thin-layer chromatography. Irradiation of the thin-layer plate with ultra-violet light after development converted tamoxifen to a fluorescent product which could be estimated in situ by densitometry. The fluorescent product was identified as a substituted phenanthrene by thin-layer chromatography, and gas chromatography--mass spectrometry. The method allowed concentrations as low as 6.8 nmol/l serum to be measured. After an oral dose of tamoxifen (10 mg) to a female patient the maximum serum concentration (66.2 nmol/l) was achieved in 3 h. When 10 mg tamoxifen were taken twice daily for 21 days by the same patient serum concentrations of about 500 nmol/l were achieved.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359080     DOI: 10.1677/joe.0.0840035

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 3.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 4.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.

Authors:  P Wilkinson; G Ribeiro; H Adam; J Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.

Authors:  P M Wilkinson; G G Ribiero; H K Adam; J V Kemp; J S Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

Review 7.  Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

8.  A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

Authors:  D G Bratherton; C H Brown; R Buchanan; V Hall; E M Kingsley Pillers; T K Wheeler; C J Williams
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.